Duration of chemotherapy with topotecan influences survival in recurrent ovarian cancer: a meta-analysis.

Objective: This meta-analysis compares the feasibility, safety and clinical outcome of long-term therapy with topotecan vs. standard treatment duration in patients with recurrent ovarian cancer.

Materials And Methods: Data of 523 patients from five clinical trials were reviewed and retrospectively allocated into two groups.